Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5748815 | 0.88 | HSP90AB1 (0.45) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL704360 | 0.84 | TACR1 (0.46) | LMNAHTTALDH1A1POLBMAPT | |
| SCHEMBL24650659 | 0.80 | GPR35 (0.43) | LMNAHTTALDH1A1POLBMAPT | |
| SCHEMBL5631284 | 0.80 | RXRA (0.49) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20349610 | 0.80 | RXRA (0.50) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL137510 | 0.79 | HSP90AB1 (0.47) | LMNAHTTALDH1A1POLBMAPT | |
| SCHEMBL27734452 | 0.78 | P2RX1 (0.42) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL25077871 | 0.78 | CYP3A4 (0.45) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL349231 | 0.78 | LMNA (0.40) | LMNAMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL24650657 | 0.78 | GPR35 (0.41) | LMNAHTTALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335673-B2 | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20040072878-A1 | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1325903-A1 | 2,3-DIPHENYLPROPIONIC ACID DERIVATIVES OR THEIR SALTS, MEDICINES OR CELL ADHESION INHIBITORS CONTAINING THE SAME, AND THEIR USAGE | Kaken Pharmaceutical Co., Ltd. (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072878-A1 | 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage | VCAM1, ICAM1, PTK2 | LMNA 2733/4885MEN1 2532/4885KMT2A 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.